Osimertinib/pembrolizumabToxic epidermal necrolysis and immune-mediated pneumonitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1845卷 / 1期

关键词：

D O I：

10.1007/s40278-021-92190-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：307 / 307

相关论文

共 50 条

[1] PembrolizumabToxic epidermal necrolysis and immune pneumonitis: case report
Reactions Weekly, 2020, 1815 (1) : 276 - 276
[2] PembrolizumabToxic epidermal necrolysis: case report
Reactions Weekly, 2020, 1795 (1) : 224 - 224
[3] PembrolizumabToxic epidermal necrolysis: case report
Reactions Weekly, 2020, 1813 (1) : 193 - 193
[4] PembrolizumabToxic epidermal necrolysis: case report
Reactions Weekly, 2023, 1944 (1) : 480 - 480
[5] PembrolizumabToxic epidermal necrolysis: case report
Reactions Weekly, 2022, 1900 (1) : 277 - 277
[6] PembrolizumabToxic epidermal necrolysis: case report
Reactions Weekly, 2017, 1646 (1) : 266 - 266
[7] Doxycycline/pembrolizumabToxic epidermal necrolysis: case report
Reactions Weekly, 2024, 2032 (1) : 162 - 162
[8] Immune-Mediated Toxic Epidermal Necrolysis
Keerty, Dinesh
Koverzhenko, Viktoriya
Belinc, Dalila
LaPorta, Katie
Haynes, Elizabeth
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (08)
[9] Gefitinib/pembrolizumabToxic epidermal necrolysis and lack of efficacy: case report
Reactions Weekly, 2023, 1967 (1) : 179 - 179
[10] A Case of Immune-Mediated Pneumonitis?
Felizardo, Margarida
Matos, Claudia P.
Furtado, Sofia T.
Teixeira, Encarnacao
Coelho, Jose P.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S239 - S240

← 1 2 3 4 5 →